导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.66% | 1930/4773 |
| 近一周 | -1.93% | 1003/5462 |
| 近一月 | -2.89% | 1705/5421 |
| 近一季 | -4.26% | 1769/5209 |
| 近半年 | 0.47% | 1213/4920 |
| 近一年 | 5.15% | 1727/4366 |
| 近两年 | 49.10% | 1525/2954 |
| 近三年 | 30.83% | 1049/2253 |
| 成立以来 | 71.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.11% 3044/4961 |
11.79% 2293/5312 |
- - |
- - |
| 2025 | 19.77% 2183/4813 |
-0.18% 2093/3635 |
1.37% 2361/4076 |
17.35% 2526/4524 |
0.86% 1709/4813 |
| 2024 | 15.67% 902/3463 |
3.50% 558/2808 |
-0.78% 834/3014 |
15.24% 1776/3129 |
-2.27% 2026/3463 |
| 2023 | -9.30% 1148/2656 |
3.29% 1223/2280 |
-3.38% 783/2385 |
-2.33% 665/2515 |
-6.96% 1992/2655 |
| 2022 | -23.16% 1113/2207 |
-13.74% 827/1919 |
5.49% 890/2016 |
-14.10% 1024/2113 |
-1.70% 1731/2208 |
| 2021 | -2.31% 845/1822 |
-2.92% 724/1255 |
6.51% 740/1330 |
-5.39% 801/1466 |
-0.14% 1205/1822 |
| 2020 | 43.44% 244/1250 |
-7.85% 574/1028 |
18.30% 344/1067 |
15.65% 204/1164 |
13.77% 331/1184 |
| 2019 | - - |
- - |
- - |
6.78% 114/850 |
9.04% 263/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华宝沪深300指数增强C VS. 长安沪深300非周期A(740101) |